Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
November 9, 2015 4:05 PM EST-Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839
-Continued Signs of Activity, Tolerability, and Durability
-First Preclinical Data Presented For Immuno-Oncology Arginase Inhibitor CB-1158
-IND filing Remains on Track for 1H 2016
-Calithera to Host Conference Call Today at 4:15pm Eastern Time
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage... More
